NeoGenomics Q1 revenue up 11% to $187M; raises FY2026 guidance to $797-803M

NEOGENOMICS INC

Consolidated revenue $187M (+11% YoY); Clinical revenue +14%, NGS +26%.
Net loss narrowed 34% to $17M; adjusted EBITDA $9M (+27% YoY).
Raised FY2026 revenue guidance to $797-803M (prior range not specified).
Launched RaDaR ST MRD assay; received MolDX coverage for PanTracer LBx.
Cash and marketable securities $146M at quarter end.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.